Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Should This News Scare Amarin Investors?

Amarin investors rejoiced this summer after the company’s drug, Vascepa, which is derived from a fish oil compound, was approved by the FDA. As a result, Amarin’s share price has nearly doubled in value since the start of 2012, and the company is poised to market the drug in early 2013. Vascepa will compete with GlaxoSmithKline’s triglyceride-lowering therapeutic Lovaza, which generated more than $900 million in sales for fiscal 2011.

However, recent studies challenge the notion that fish oil has positive benefits for the cardiovascular system. Does this news put Amarin’s future drug sales in jeopardy? Healthcare bureau chief Brenton Flynn, and analyst Max Macaluso, discuss the news in the video below.


Amarin has had a great run so far this year, but it didn’t make our list of the three Middle-Class Millionaire-Makers that Wall Street’s too rich to notice. These stocks might be ignored by the 1%, but they could boost the returns in your portfolio -- just click here to read it now.


Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (7) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 15, 2012, at 9:36 AM, skm1965 wrote:


    If you want to read more: Click interview with Dr.Bhatt a top cadiologist-who is overseeing OUTCOME study-Reduce-IT. His comments on Origin-6 years study are there as well as JELIS study URL for details.

    Key to VASCEPA-for 4mg dose/day:

    1) It reduces trigylcerides

    2) But more importantly other Lipid profile data including C-reactive Protein(GOLDEN Marker for inflammation and coronary artery disease).

    Lovaza lowers trigylcerides,but not CRP and raises LDL.

    Out COME study(Reduce-IT) results won't be known until 2015 or 2016--but odds are high based on JELIS results that it will prove to more effective in reducing Heart Attacks and Strokes.

    You can see Amarin's investor-presentation.pdf to see AMR101 compared to JELIS and LOVAZA on Amarin's investor website.

  • Report this Comment On September 15, 2012, at 12:28 PM, NoPanicBill wrote:

    Your article has a terrible flaw. It is relying on a apples to oranges article. You fail to mention the findings were based on many over the counter FISH oil or non-pure SUPLIMENTS. AMRN is not a fish oil and it is almost 100% pure. There are clear medical differences. 8 large institutions have BUY ratings for AMRN with target prices ranging from $22-28 per share without a buyer for AMRN based on the FDA approval of the Marine study. This gives AMRN a valuation of approximately $2 billion. Many experts believe a buyout would bring a price of $35-45 with only one bidder. In October AMRN will file for FDA approval of the Anchor trial results. After this expected approval in late fall 2013 the company will have an estimated value of 6-8 billion dollars. The longer any of the major pharmaceutical companies take to buyout AMRN will result in a much higher bid price. The Reduce-It study will enhance the valuation incredibly. It is important to remember that this new study is being performed at the request of the FDA at a cost to AMRN of about $120 million. This solidifies that the FDA recognizes AMRN's product can reduce/prevent these life threatening conditions. The Options Market would also seem to confirm this by looking at the overwhelming amount of calls purchased over puts purchased. You can often use Option totals as a gauge to which direction a stock will go over time. My advise to anyone after you read an article is to never panic to get out or in without doing more investigation on any stock. Use common sense and you will find that you will be right much more than wrong. Articles like this and the article that they have wrote about cause bad judgement and often will provide a buying opportunity after the panic stricken jump off the cliff. Remember, look for more concrete information from reputable investment groups then read, think, read, think before you react.

  • Report this Comment On September 15, 2012, at 1:01 PM, idahithat wrote:

    although you did try to clear up some of the differences later in the vidy, before you recorded the session, you really educate yourself on the difference between a CLINICAL study ( words you used to refer to it ) and a META-STUDY which is actually the recent news on "fish oil'. A meta study is a data mining expedition, a literature review.

    Additionally, the meta study was concerned with variable but low doses of all sorts & comers of OTC fish oils, uncontrolled and variably defined populations, and even the relatively unknown greek author of said study ( best known to me for his "Drinking Cola causes Paralysis" contribution to the world) pointed out that the meta study did not refute fish oil efficacy, rather was not capable of proving it. Furthermore, the disagreements with even that conclusion the meta study are already rolling in.

    All told, this meta study seems to be a plus for Vascepa or at least a hole in OTC fish oil claims; Vascepa is NOT fish oil, rather it is a single compound DERIVED from fish oil, and one of the main benefits with Vascepa, over a less refined fish oil based pharmaceutical like Lovaza, was the removal of the DHA compound, DHA is known to raise LOW density lipos, which is counter productive to heart health. Vascepa, (near pure EPA) is proven to reduce triglyerides without raising LDL. See what your doctor or cardio thinks of that plan

  • Report this Comment On September 15, 2012, at 11:22 PM, jmarsh164 wrote:


  • Report this Comment On September 16, 2012, at 1:16 AM, steven107 wrote:

    I have heard on news and read online about how over the counter herbal food supplements can be found to have very little or too much active ingredients, all filler and no active ingredients, similar looking but different active ingredient, actual drug product not mentioned in ingredients, ectetera... also ingredients taken from wrong part of plant which causes it to have toxins, since many plants have toxic substances in roots or leaves or stems, important to keep focus on the part of the plant intended to be consumed.

    That is why I think all studies done on herb type products, are a waste of money. They would have to purchase raw herbs, have plant material tested (I heard in news that people that collect plant material will pass off similar looking but more common plants), encapsulated, etc; otherwise at the end of the study they will not have learned anything.

    If they just let people purchase random product at the store then all patients potentially taking different doses, different products, different toxins, etc.

    As for fish oil pills, I would worry about pcb's, mercury and whatever else we have dumped in the water that fish collect in their tissues.

  • Report this Comment On September 16, 2012, at 2:25 PM, skm1965 wrote:

    Pl.Click on JELIS Study of EPADEL.

    Epadel is being used with Statins in Japan.

    Vascepa should be used with Lipitor or Crestor based on your doctor's advice.

    ORIGIN Study published in New England Journal Of Medicine in July,2012--uses LOVAZA/OMACOR--PRONOVA has the patents for Lovaza and OMACOR.If you read the ORIGIN study-it says funded by SANOFI and drugs supplied by PRONOVA.

    Lovaza has EPA as well as DHA--like Over the counter fish oils.The only difference is that Lovaza was approved by FDA--for reducing triglycerides.

    Just reducing trigylcerides is NOT enough-- Good product must reduce other LIPID profile as well as C-RP.

  • Report this Comment On September 16, 2012, at 2:27 PM, skm1965 wrote:


    No panicbill comments are worth noting.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2017989, ~/Articles/ArticleHandler.aspx, 10/27/2016 8:58:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
AMRN $3.41 Down -0.04 -1.16%
Amarin CAPS Rating: ****
GSK $40.42 Up +0.08 +0.20%
GlaxoSmithKline CAPS Rating: ***